Overview

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

Status:
Terminated
Trial end date:
2005-02-14
Target enrollment:
Participant gender:
Summary
Current therapies for Stage IV Melanoma provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV Melanoma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage IV Melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Burzynski Research Institute